Finding miRNA targeting PI3K/Akt/mTOR signaling pathway in human breast cancer cells

Publish Year: 1394
نوع سند: مقاله کنفرانسی
زبان: English
View: 436

نسخه کامل این Paper ارائه نشده است و در دسترس نمی باشد

  • Certificate
  • من نویسنده این مقاله هستم

این Paper در بخشهای موضوعی زیر دسته بندی شده است:

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

ICBCMED12_203

تاریخ نمایه سازی: 2 تیر 1397

Abstract:

Background: breast cancer is the first common cancer among women worldwide. One of the major signaling pathways playing a role in the onset and progression of the disease is PI3K/Akt/mTOR, which is inhibited by PTEN. miRNAs are small non-coding molecules that regulate the expression of their targets by inhibition or suppression, and thus their dysregulated expression results in the development of cancer. Materials and methods: using various software applications predicting miRNAs, miR-144 was selected as the inhibitor of PTEN. The expression of miR-144 and PTEN has been evaluated by GEO microarray data, GSE57515 and GSE60716 in breast cancer cell lines and patient samples respectively. Results: PTEN and miR-144 expression analysis showed decreased levels of PTEN in patient samples and increased levels of miR-144 in breast cancer cell lines Conclusion: The results showed that the expression of PTEN and miR-144 was inversely correlated in more breast cancer metastatic cell lines indicating inhibitory effects of miR-144 on PTEN. Therefore, miR- 144 can probably be used in invasive and metastatic cancers as a biomarker either alone or in conjunctionwith other markers.

Authors

Vahid Kia

Cellular and Molecular Biology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Vahedeh Hosseini

Department of Medical Biotechnology and Nanotechnology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.

Samira Mohammadi-Yeganeh

Department of Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran